To more directly assess the relevance of ERK activation in the proliferation of DIH, we treated F/F and Δ/Δ DIH with GDC-0879, a potent and specific RAF inhibitor, or with the multikinase inhibitor Sorafenib, used in the treatment of advanced HCC. Here, RAF1 is linked to hepatocellular carcinoma.